{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-022615","form_type":"8-K/A","ticker":"PTGX","cik":"0001377121","company_name":"Protagonist Therapeutics, Inc","filed_at":"2025-03-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.471490+00:00","generated_at":"2026-05-24T23:24:54.991120+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Icotrokinra shows positive Phase 2b UC (corrected p-value) and Phase 3 PsO top-line data","bullets":["Phase 2b ANTHEM-UC: highest dose achieved 63.5% clinical response and 30.2% clinical remission at Wk12 vs 27.0% and 11.1% placebo; p-values corrected to <0.001 and <0.01.","Phase 3 ICONIC-LEAD: 65% IGA 0/1 and 50% PASI 90 at Wk16; at Wk24: 74% IGA 0/1, 65% PASI 90; 46% completely clear skin.","Phase 3 ICONIC-ADVANCE 1&2: met co-primary endpoints vs placebo; superior to deucravacitinib on all key secondary endpoints at Wk16 and Wk24.","Initiation of ICONIC-ASCEND: first head-to-head study of oral icotrokinra vs injectable biologic (ustekinumab) in moderate-to-severe PsO."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-022615","json":"https://secwatch.observer/filing/0001104659-25-022615.json","markdown":"https://secwatch.observer/filing/0001104659-25-022615.md","text":"https://secwatch.observer/filing/0001104659-25-022615.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1377121/000110465925022615/0001104659-25-022615-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1377121/000110465925022615/tm258886d1_8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T23:24:54.991120+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}